

## cDPCP biochemical

cDPCP

CATALOG #  
AAA227205


### PRODUCT SYNONYMS

cDPCP; DTIC citrate; cDPCP biochemical

### PRODUCT SPECIFICATIONS


|                         |                                                                                                                    |
|-------------------------|--------------------------------------------------------------------------------------------------------------------|
| Purity/Purification     | 98%                                                                                                                |
| SMILES                  | [Cl-].[Pt+2]([NH3][N]1=CC=CC=C1)[NH3].[Cl-]                                                                        |
| Formula                 | C5H11ClN3Pt·Cl                                                                                                     |
| CAS                     | 106343-59-3                                                                                                        |
| Solubility              | H2O: Slightly soluble<br><br>DMSO: Slightly soluble<br><1mg/ml refers to the product slightly soluble or insoluble |
| Preparation and Storage | Powder: -20 degree C for 3 years<br>In solvent: -80 degree C for 2 years                                           |

### IMAGES



Structure

Dacarbazine citrate, CAS 64038-56-8



Structure

Dacarbazine citrate, CAS 64038-56-8

### ADDITIONAL INFORMATION

#### Related Product Information for cDPCP biochemical

cDPCP is a platinum-containing DNA-crosslinking agent.<sup>1</sup>Unlike cisplatin or oxaliplatin, cDPCP forms monofunctional DNA adducts. It is transported into cells by organic cation transporter 1 (OCT1) and OCT2, inhibiting proliferation of MDCK cells expressing the human transporters with IC<sub>50</sub> values of 8.1 and 1.5 μM, respectively. cDPCP inhibits RNA polymerase II-mediated transcription in a reporter assay using HeLa cells. It increases survival in murine S180 sarcoma and P388 leukemia models when administered at doses of 40 and 80 mg/kg, respectively.<sup>2</sup>

## References

1. Di Martino A, Sedlarik V. Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. *Int J Pharm.* 2014 Oct 20;474(1-2):134-45. doi: 10.1016/j.ijpharm.2014.08.014. Epub 2014 Aug 12. PubMed PMID: 25124059.
2. Stark P, Steinmetz A, Hefetz M, Hardoff R. Misleading Ga-67 uptake in a patient with Hodgkin's disease, mediastinal deviation, and pulmonary compression. *Clin Nucl Med.* 2002 Dec;27(12):898-9. PubMed PMID: 12607876.
3. St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. *J Neurooncol.* 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28. PubMed PMID: 26311249.
4. Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. *Cancer Treat Rep.* 1984 Mar;68(3):499-504. PubMed PMID: 6704980.

## NCBI AND UNIPROT INFORMATION

### Molecular Weight

374.31

**For Research Use Only.** Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | [contact@aaabiotech.com](mailto:contact@aaabiotech.com)

Online datasheet: <https://www.aaabiotech.com/biochemical/cdpcp/227205>